A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. by Potter, Laura A et al.
UC Davis
UC Davis Previously Published Works
Title
A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum 
Disorder.
Permalink
https://escholarship.org/uc/item/4vg8m00v
Journal
Frontiers in Psychiatry, 10
ISSN
1664-0640
Authors
Potter, Laura A
Scholze, Danielle A
Biag, Hazel Maridith B
et al.
Publication Date
2019
DOI
10.3389/fpsyt.2019.00810
License
https://creativecommons.org/licenses/by/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Edited by: 
Sara Calderoni, 
Fondazione Stella Maris (IRCCS), 
Italy
Reviewed by: 
Cristan Farmer, 
National Institute of Mental Health 
(NIMH), 
United States 
Leandro Da Costa Lane Valiengo, 
University of São Paulo, Brazil
*Correspondence: 
Laura A. Potter 
Lfapotter@gmail.com
Specialty section: 
This article was submitted to 
 Child and Adolescent Psychiatry, 
 a section of the journal 
 Frontiers in Psychiatry
Received: 29 June 2019
Accepted: 14 October 2019
Published: 06 November 2019
Citation: 
Potter LA, Scholze DA, Biag HMB, 
Schneider A, Chen Y, Nguyen DV, 
Rajaratnam A, Rivera SM, 
Dwyer PS, Tassone F, Al Olaby RR, 
Choudhary NS, Salcedo-Arellano MJ 
and Hagerman RJ (2019) A 
Randomized Controlled Trial of 
Sertraline in Young Children With 
Autism Spectrum Disorder. 
 Front. Psychiatry 10:810. 
 doi: 10.3389/fpsyt.2019.00810
A Randomized Controlled Trial of 
Sertraline in Young Children With 
Autism Spectrum Disorder
Laura A. Potter 1*, Danielle A. Scholze 2, Hazel Maridith B. Biag 1, Andrea Schneider 1,3,4, 
Yanjun Chen 5, Danh V. Nguyen 6, Akash Rajaratnam 7, Susan M. Rivera 1,8, 
Patrick S. Dwyer 9, Flora Tassone 1,10, Reem R. Al Olaby 11, Nimrah S. Choudhary 10, 
Maria J. Salcedo-Arellano 1 and Randi J. Hagerman 1,3
1 Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, UC Davis Health, Sacramento, CA, United States, 
2 Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States, 
3 Department of Pediatrics, UC Davis Health, Sacramento, CA, United States, 4 College of Psychology, California Northstate 
University, Elk Grove, CA, United States, 5 Institute for Clinical and Translational Science, University of California, Irvine, Irvine, 
CA, United States, 6 Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, United States, 
7 Case Western Reserve University School of Medicine, Cleveland, OH, United States, 8 Department of Psychiatry and 
Behavioral Sciences, UC Davis Health, Sacramento, CA, United States, 9 Department of Psychology, University of California, 
Davis, Davis, CA, United States, 10 Department of Biochemistry and Molecular Medicine, UC Davis Health, Sacramento, CA, 
United States, 11 College of Health Sciences, California Northstate University, Rancho Cordova, CA, United States
Objective: Selective serotonin reuptake inhibitors like sertraline have been shown in 
observational studies and anecdotal reports to improve language development in young 
children with fragile X syndrome (FXS). A previous controlled trial of sertraline in young 
children with FXS found significant improvement in expressive language development as 
measured by the Mullen Scales of Early Learning (MSEL) among those with comorbid 
autism spectrum disorder (ASD) in post hoc analysis, prompting the authors to probe 
whether sertraline is also indicated in nonsyndromic ASD.
Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose 
sertraline in a randomized, double-blind, placebo-controlled trial in 58 children with ASD 
aged 24 to 72 months.
Results: 179 subjects were screened for eligibility, and 58 were randomized to sertraline 
(32) or placebo (26). Eight subjects from the sertraline arm and five from the placebo 
arm discontinued. Intent-to-treat analysis showed no significant difference from placebo 
on the primary outcomes (MSEL expressive language raw score and age equivalent 
combined score) or secondary outcomes. Sertraline was well tolerated, with no difference 
in side effects between sertraline and placebo groups. No serious adverse events possibly 
related to study treatment occurred.
Conclusion: This randomized controlled trial of sertraline treatment showed no benefit 
with respect to primary or secondary outcome measures. For the 6-month period, 
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inTRODUCTiOn
Autism spectrum disorder (ASD) is a behaviorally defined 
developmental disorder characterized by deficits in social 
communication and interaction in conjunction with the presence 
of restricted, repetitive patterns of behavior (1). Speech delay and 
other language deficits are common in early development. ASD 
is understood to have many causes, including an estimated over 
1,000 gene mutations that can lead to deficits in synaptic plasticity, 
neuronal migration, transcription and translation changes, 
and many other processes important for synapse development 
and central nervous system (CNS) connectivity (2). Currently, 
the Centers for Disease Control and Prevention reports that 1 
in 59 children at age 8 years in the general U.S. population has 
ASD (3). Known specific causes accounting for more than 2 
to 3% of all ASD cases include fragile X syndrome (FXS) and 
tuberous sclerosis, although many more single gene mutations, 
duplications, or deletions can cause 1% or less of cases. In 
individuals with ASD compared to neurotypical controls, higher 
rates of putative functional de novo mutations are observed (1), 
and whole genome sequencing can identify genetic mutations in 
up to 30% of those with ASD (4). As many as 50% of de novo 
mutations resulting in ASD appear to occur in genes regulated 
by or associated with FMRP, the protein lacking in patients with 
FXS due to methylation of the FMR1 gene on the X chromosome, 
suggesting a potential overlap in beneficial treatments between 
FXS and ASD (5).
There is growing evidence of a sensitive period in the 
development of young children with neurodevelopmental 
problems, during which the brain is rapidly developing and thus 
may be more susceptible to intervention with targeted treatments 
(6–12). Targeted behavioral interventions in ASD, such as the Early 
Start Denver Model, demonstrate improvements in behavioral 
and developmental symptoms as well as electroencephalogram 
parameters for children under 5 years, compared with community 
intervention (13, 14). Pharmacological interventions in children 
under 6 years with ASD may also be warranted, but few clinical 
trials have been conducted to date.
Disruption of serotonergic development has long been 
suggested as a causal factor in the altered brain function and 
behaviors seen in neurological disorders including autism. 
Positron emission tomography scanning has demonstrated 
that young children with ASD show lower levels of serotonin 
production compared with neurotypically developing controls 
during the first 5 years of development, when rapid synapse 
formation typically takes place (15). Further, using lymphoblastoid 
lines, a metabolomics study of several forms of ASD revealed 
a deficit of the enzymes needed to convert tryptophan into 
serotonin (16). Such evidence has spurred research into whether 
selective serotonin reuptake inhibitors (SSRIs) like sertraline 
could reverse the neurophysiological changes observed in ASD.
Sertraline is currently approved by the Food and Drug 
Administration for the treatment of Obsessive Compulsive 
Disorder in children aged 6 to 17 years, as well as several 
psychological disorders including major depressive disorder and 
social anxiety disorder in adults. In clinical practice, sertraline has 
been used to treat self-injury, aggression, anxiety, and depressed 
mood in individuals with ASD. Sertraline has been proposed as 
an optimal SSRI for ASD because of its lesser activating effects 
compared to other psychotropic medications and its minimal 
interaction with the metabolism of other medications compared 
with other SSRIs.
Animal studies have further investigated the effects of 
SSRIs like sertraline on various biomarkers related to early 
development in ASD and other neurological disorders. There 
is evidence in mouse models of Down syndrome that SSRIs 
stimulate brain-derived neurotrophic factor (BDNF) when 
given early in development (17). BDNF levels are correlated with 
late-phase long-term potentiation in mice, synapse regulation 
and cognitive function in adult humans, and behavioral 
changes such as susceptibility to anxiety and aggression in 
both mice and humans (18, 19). Clinical evidence suggests 
altered serum concentrations of BDNF in children with ASD 
compared to controls, though CNS levels are not known (20). 
Pro-cognitive and neuroprotective effects were seen in wild-
type mice treated with sertraline, with a supposed mechanism 
in which sertraline’s upregulation of BDNF in turn upregulated 
serotonin, dopamine, and gamma-aminobutyric acid 
(GABAergic) systems (21). In the knockout FXS mouse model, 
BDNF treatment also rescued synaptic plasticity (22). Abdallah 
et al. showed that matrix metalloproteinase-9 (MMP9), an 
endopeptidase implicated in early postnatal synaptogenesis (7, 
23), was elevated in the amniotic fluid of ASD cases compared 
to controls. Additionally, increased levels of brain serotonin in 
mice have been shown to correlate with MMP9 activity, making 
both BDNF and MMP9 possible biomarkers of treatment with 
SSRIs in ASD (24, 25).
Few clinical trials of SSRIs and other serotonin-influencing 
drugs have been conducted to date in children under 6 years 
with idiopathic or syndromic ASD, perhaps due to the overall 
negative results of studies of SSRIs in their older child and 
adolescent counterparts to date (26); however, those trials in 
young children that have been published have shown promising 
results (27–29). In 2012, a retrospective study of low-dose 
sertraline in 45 children with FXS with and without ASD aged 
12 to 50 months demonstrated significant improvements in 
treatment in young children with ASD appears safe, although the long-term side effects of 
low-dose sertraline in early childhood are unknown.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02385799.
Keywords: sertraline, autism spectrum disorder, controlled trial, targeted treatment, nonsyndromic autism 
spectrum disorder
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the trajectory of receptive and expressive language in those on 
sertraline compared with those not treated with sertraline (27). In 
prespecified secondary analyses, Chugani et al. showed that low-
dose buspirone, a partial serotonin receptor agonist, in children 
aged 2 to 6 years with ASD could be an effective treatment to 
reduce restrictive and repetitive behaviors in conjunction with 
behavioral interventions (28). Greiss Hess et al. demonstrated the 
benefit of low-dose sertraline (2.5 to 5.0 mg/day) in children with 
FXS with and without ASD aged 2 to 6 years with improvements 
in secondary outcomes of visual reception, fine motor, and 
cognitive T score sum on the Mullen Scales of Early Learning 
(MSEL) (29). The children receiving sertraline also performed 
better than those in the placebo group on a passive-viewing eye 
tracking (PVET) task of receptive vocabulary post-treatment 
compared to baseline (30). Moreover, polymorphisms of several 
genes involved in the serotonergic pathway, such as BDNF and 
5-HTTLPR (serotonin-transporter-linked polymorphic region), 
were identified as potential predictors of response to sertraline 
treatment for these children (31). In post hoc analysis, those with 
both FXS and ASD demonstrated significant improvements 
on sertraline compared to placebo in expressive language 
development on the MSEL (29). These results prompted the 
authors to carry out the study reported here to investigate 
whether sertraline has a similar benefit in young children with 
nonsyndromic ASD.
MATERiAlS AnD METHODS
Participants and Design
This was an exploratory first trial of sertraline in children with 
non-FXS ASD aged 2 to 6 years using a randomized, double-
blind, placebo-controlled, parallel two-arm design between April 
2015 and July 2018. Inclusion criteria included documentation of 
ASD as verified using both Diagnostic and Statistical Manual, 5th 
edition (DSM-5) and Autism Diagnostic Observation Schedule, 
2nd edition (ADOS-2) criteria, age between 24 and 72 months, 
stable medications (including antiepileptics, antipsychotics, 
and clonidine) in the 2 months prior to enrollment, and 
concurrent enrollment in at least one community or school 
intervention for ASD. Changes in concomitant medications 
and interventions were discouraged unless medically necessary 
during the trial. Exclusion criteria included current or past 
SSRI treatment, diagnosis of the FXS full mutation, or any other 
serious co-morbid medical disorders affecting brain function 
and behavior, including uncontrolled seizures. Molecular testing 
to rule out FXS diagnosis was carried out by PCR approach as 
described in Tassone et al. (32).
The UC Davis Investigational Drug Services independently 
carried out randomization to sertraline or placebo. The placebo 
was formulated as a clear, colorless solution and contained 
menthol so as to match both the appearance and smell of the 
liquid sertraline. The study drug was administered orally in 
liquid form (20 mg/ml), and dose was assigned based on age at 
enrollment: subjects under 4 years received sertraline or placebo 
liquid in a dose of 2.5 mg/day (0.125 ml) for the duration of the 
trial, and subjects 4 years or older received 5.0 mg/day (0.25 ml). 
These doses were based on those used in previous studies in 
young children with FXS (27, 29).
Assessments
With the exception of the Clinical Global Impression Scale—
Severity (CGI-S; completed only at baseline) and the Clinical 
Global Impression Scale—Improvement (CGI-I; completed 
only at 3 months and EOT), all assessments described 
forthwith were conducted in clinic at baseline and end-of-
treatment (EOT) visits.
Subject assessments included the four subtests of the MSEL, 
which were administered to assess changes in visual reception, 
fine motor, receptive language, and expressive language abilities. 
The Preschool Language Scales—Fifth Edition (PLS-5) was used 
to further evaluate auditory comprehension and expressive 
communication skills. A 30-trial passive-viewing eye tracking 
(PVET) task was also administered as described in Yoo et al. (30). 
In PVET trials, subjects looked at images of a target word and a 
distractor; an audio recording (e.g., “Look at the ball”) was used 
to indicate the target.
Caregiver assessments included the Visual Analog Scale 
(VAS), measuring parent-reported severity of three target 
behaviors: obsessive-compulsive behavior/anxiety, language/
communication, and hyperactivity/hyperarousal/aggression. 
Other caregiver assessments included the Vineland Adaptive 
Behavior Scales—Second Edition (VABS-II) survey interview 
to assess level of adaptive functioning; the Aberrant Behavior 
Checklist—Community (ABC-C) to measure the severity of 
certain problematic behaviors; the Preschool Anxiety Scale—
Revised (PAS-R) to assess symptoms of anxiety and fears; the 
Sensory Processing Measure—Preschool (SPM-P) to measure 
sensory processing difficulties; and the Social Responsiveness 
Scale (SRS-2) to measure ASD symptom severity in natural 
social settings.
A 3-month supply of study drug and a caregiver dosing 
diary were dispensed at baseline and again at 3 months, and 
both remaining drug and diary were collected at subsequent 
visits to measure compliance. Safety monitoring consisted of 
a physical examination at every visit, weekly telephone calls in 
the first month and monthly calls thereafter, and baseline and 
EOT standard blood laboratory tests, including comprehensive 
metabolic panel and complete blood count with differential. 
When blood volume allowed, BDNF and MMP9 levels were 
measured at both baseline and EOT.
Statistical Analyses
The study design included two primary outcomes: MSEL expressive 
language (EL) raw score and MSEL age equivalent combined (AEC) 
score (an average of visual reception, fine motor, receptive language, 
and EL subtest age equivalent scores). The primary outcome 
measures were determined based on the prior study of sertraline 
in young children with FXS (29). Prespecified efficacy analyses 
were based on the analysis of covariance (ANCOVA), adjusted for 
corresponding baseline score. All other measures and associated 
analyses were secondary/exploratory. Data from the PVET task 
were analyzed using the eyetrackingR package (33). The proportions 
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of fixation duration to the target and distractor word areas of interest 
were calculated during a window spanning 2,300–3,800 ms (i.e., 300–
1,800 ms following audio onset of the target word). PVET trials were 
excluded from the analysis if participants did not fixate to either the 
target or distractor area of interest for at least 25% of the time during 
the analysis window; recordings were also excluded if usable data 
were available on fewer than 25% of trials. T-test was used for CGI-I. 
All other secondary analyses were based on the ANCOVA model for 
continuous outcomes with baseline measures and were implemented 
in SAS software version 9.4. Adverse events (AEs) were summarized 
by severity, relation to drug, and resolution status (ongoing vs. not 
ongoing). Student’s t-test and Fisher’s exact test were applied to 
continuous and categorical demographic variables, respectively. 
Tests for primary efficacy analyses were at adjusted significance level 
0.025, while all other tests (exploratory) were at level 0.05. Post hoc 
analysis exploring whether baseline BDNF or MMP9 level or change 
in BDNF were associated with differential outcome improvement 
were based on regression model with the addition of each of these 
variables and the interaction with treatment term. The ANCOVA 
assumes a continuous (interval level) outcome, and it should be 
noted that this assumption does not in fact hold for the raw scores 
in these analyses. Also, distributions of variables were examined 
graphically, and where appropriate sensitivity analyses based on log-
transformation were conducted and results remained the same.
The study was designed with 80% power to detect a 
standardized effect size of approximately 0.68 in a 2-arm parallel 
design with the endpoint at 6 months with significance level 
of 0.025 for two primary measures. The required total sample 
size was 60 (30 per group), but resource limitations limited the 
number of randomized, analyzable patients to 47. Calculation 
of “observed” power has been shown to be scientifically invalid 
and was therefore not performed (34). Under the current 
design conditions, a reduced sample size of ~47 (i.e., at study 
completion) affords 68% power (a reduction from the planned 
80% power). We note that given that the study results suggest a 
potential effect size of 0.12, a future study would require 1,084 
patients to detect such a small effect size. Because this small effect 
size is clinically not meaningful, such a future study would be 
ethically unacceptable.
RESUlTS
Subject Characteristics
Of the 179 subjects contacted regarding the study, 81 were assessed 
for eligibility, and 58 participants met inclusion criteria and agreed 
to participate (Figure 1). The 58 participants were randomized 
to the sertraline arm (n = 32) or placebo arm (n = 26). Baseline 
characteristics between groups are shown in Table 1. The majority 
of participants in the treatment arms (sertraline vs. placebo) were 
boys (78 vs. 81%), spoke English as their primary language (94 vs. 
88%), and identified as Caucasian (59 vs. 69%). There were more 
non-Hispanic participants in the sertraline arm than the placebo 
arm (91 vs. 69%). The average (SD) age was 4.3 (0.8) and 3.7 (1.1) 
years in the sertraline and placebo groups, respectively. Level of 
education of the primary caregiver, ADOS-2 classification, and 
use of concomitant medication showed no significant difference 
between treatment groups. None of the subjects had a molecular 
diagnosis of FXS. A total of 13 subjects discontinued (8 from the 
sertraline arm and 5 from the placebo arm); of these, only 2 in the 
sertraline arm voluntarily returned to complete EOT assessments. 
Thus, 45 participants completed 6 months of treatment, and a 
total of 47 were analyzed.
Prespecified Primary Outcome Analysis
Prespecified intent-to-treat (as randomized) analyses were 
conducted for 2 designated primary outcome measures: MSEL 
EL raw score and MSEL age equivalent combined (AEC) score. 
Observed changes in scores at follow-up, adjusted for baseline 
scores, were not significantly different between sertraline and 
placebo groups (Table 2): EL raw score mean 20.3 (11.7) vs. 21.8 
(14.3), F1,44 = 0.37, p = 0.547; AEC score mean 28.2 (14.2) vs. 30.3 
(15.6), F1,44 = 1.11, p = 0.298.
Secondary/Exploratory Outcome 
Measures and Post Hoc Analyses
Secondary measures included MSEL subtest raw and age equivalent 
scores in visual reception, fine motor, and receptive language; 
CGI-I at EOT; PLS-5 auditory comprehension and expressive 
communication raw and age equivalent scores; PVET; Visual 
Analog Scale for each of the three prespecified target behaviors 
at EOT; VABS-II; ABC-C; PAS; SRS; and SPM-P. Overall, in all 
secondary measures there was no difference between sertraline and 
placebo groups (Table 3), with the exception of MSEL fine motor 
age equivalent score, for which the mean improvement, adjusted 
for baseline score, was smaller for sertraline than placebo [mean 
difference: -2.9, 95% confidence interval (CI): -5.7 to -0.20]. Also, 
CGI-I at 3 months was examined as a post hoc analysis, and there 
was no difference between groups (F1,48 = 0.17, p = 0.866). Notably, 
for the aforementioned reasons for exclusion of data, usable PVET 
recordings were available for only 14 subjects (7 sertraline, 7 
placebo) at both baseline and EOT. Repeated-measures ANOVA 
with treatment group as a between-subjects factor and time point as 
a within-subjects factor revealed no main effect of treatment group 
(F1,12 = 0.005, p = 0.94), no main effect of time point (F1,12 = 0.072, 
p = 0.79), and no interaction (F1,12 = 0.126, p = 0.73).
Given the older average age of the sertraline group, age was 
incorporated as a covariate in the post hoc analysis of treatment 
effect. The results were consistent: treatment group difference 
was not significant for AEC score (F1,43 = 1.26, p = 0.267) and EL 
raw score (F1,43 = 0.28, p = 0.600). In both analyses, age was not 
associated with AEC score (F1,43 = 1.20, p = 0.280) and EL raw 
score (F1,43 = 3.04, p = 0.089).
Correlation of Matrix Metalloproteinase-9 
and Brain-Derived neurotrophic Factor 
With Outcome
Higher baseline MMP9 was associated with lower MSEL AEC 
score (slope estimate = -0.95, F1,39 = 5.37, p = 0.026) in all subjects 
(sertraline and placebo); however, there was no difference in 
outcome between treatment groups across levels of MMP9 
(F1,39 = 0.62, p = 0.437). Similarly, for MSEL EL raw score, there 
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was no difference between groups at all levels of MMP9 (F1,39 = 
0.06, p = 0.812), and MMP9 was not associated with outcome 
(F1,39 = 1.38, p = 0.247). Due to insufficient blood volume, MMP9 
measurement at EOT was not available for analysis.
Baseline BDNF was not associated with MSEL AEC score 
(F1,39 = 3.55, p = 0.067) or EL raw score (F1,39 = 1.96, p = 0.170), 
and there was no difference in outcome between groups across 
all levels of baseline BDNF (F1,39 = 1.14, p = 0.293 and F1,39 = 
2.40, p = 0.129 for MSEL AEC and EL raw scores, respectively). 
These results were the same for the secondary outcome of CGI-I 
at EOT, as well as for CGI-I at 3 months.
Further analyses were undertaken to examine whether changes 
in BDNF were related to improvement in outcomes. Change in 
BDNF was not associated with all outcomes, and there was no 
difference in outcomes between sertraline and placebo groups at all 
levels of change in BDNF. There was no difference in mean changes 
in BDNF levels between sertraline [mean 833.6 (SD 1081.2)] and 
placebo [mean 806.6 (SD 1578.7); t36 = 0.06, p = 0.952].
FiGURE 1 | CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials.
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TABlE 1 | Baseline characteristics of study subjects.
Variable Category Sertraline (n = 32) Placebo (n = 26) P-value*
n % n %
Age Mean/SD 4.31 0.90 3.70 1.10 0.0475
MSEL DQ Mean/SD 48.72 21.46 50.63 24.05 0.7790
MSEL DQ V Mean/SD 35.84 21.89 42.58 31.24 0.4020
MSEL DQ NV Mean/SD 53.01 21.95 53.31 22.25 0.9630
Sex Male 25 78.13 21 80.77 1
Female 7 21.88 5 19.23
Primary language English 30 93.75 23 88.46 0.6482
Other 2 6.25 3 11.54
ADOS-2 ASD 2 6.25 1 3.85 1
Autism 30 93.75 25 96.15
Race Caucasian 19 59.38 18 69.23 0.6396
Black 5 15.63 2 7.69
Asian 7 21.88 4 15.38
Other/unknown 1 3.13 2 7.69
Ethnicity Non-Hispanic/Latino 29 90.63 18 69.23 0.0496
Hispanic/Latino 3 9.38 8 30.77
Education Unknown 8 25 9 34.62 0.5897
Partial college 10 31.25 5 19.23
College degree 7 21.88 8 30.77
Graduate degree/ 7 21.88 4 15.38
professional training
Concomitant No 29 90.63 24 92.31 1
Medication Yes 3 9.38 2 7.69
*Fisher’s exact test.
SD, standard deviation; MSEL, Mullen Scales of Early Learning; DQ, developmental quotient; V, verbal; NV, nonverbal; ADOS-2, Autism Diagnostic Observation 
Schedule, 2nd edition; ASD, autism spectrum disorder.
TABlE 2 | Primary efficacy results.
Variables Sertraline Placebo
Baseline End-of-treatment Baseline End-of-treatment
n Mean SD n Mean SD n Mean SD n Mean SD P-value, F
MSEL EL raw score 32 18.19 10.39 26 20.31 11.70 26 19.69 11.69 21 21.81 14.29 0.5467, F1,44 = 0.37
MSEL AEC score 32 24.98 12.79 26 28.16 14.15 26 25.61 11.73 21 30.30 15.58 0.2976, F1,44 = 1.11
SD, standard deviation; MSEL, Mullen Scales of Early Learning; EL, expressive language; AEC, age equivalent combined.
TABlE 3 | Results of secondary measures.
Variables Sertraline Placebo
Baseline End-of-treatment Baseline End-of-treatment
n Mean SD n Mean SD n Mean SD n Mean SD P-value, F
MSEL ELC standard score 32 56.66 11.41 26 56.31 12.28 26 58.88 14.44 21 60.95 19.72 0.0797, F1,44 = 3.22
PLS-5 total raw score 30 43.03 23.35 25 51.40 23.56 26 48.65 25.57 21 57.24 26.26 0.736, F1,42 = 0.12
CGI-I 26 1.23 1.11 21 1.14 0.96 0.7757, F1,45 = 0.08
VAS: A/OCB 32 4.87 2.58 26 6.48 2.61 25 4.98 2.30 20 6.86 2.37 0.7635, F1,43 = 0.09
VAS: L/C 31 2.03 1.70 25 4.70 2.73 25 2.84 2.04 21 5.53 2.95 0.9043, F1,43 = 0.01
VAS: A/H/H 32 4.52 2.51 26 5.64 2.71 26 4.30 2.49 21 6.61 2.46 0.2167, F1,44 = 1.57
VABS-II ABC 32 68.03 12.15 25 69.68 15.14 26 68.50 11.14 21 71.52 15.47 0.8691, F1,43 = 0.03
ABC-C composite score 32 57.25 29.58 26 49.85 32.69 25 57.96 24.15 21 43.91 24.99 0.2907, F1,44 = 1.14
PAS-R total raw score 32 14.75 11.58 26 14.77 14.45 24 15.38 12.51 21 11.43 10.04 0.1947, F1,43 = 1.74
SRS-2 total raw score 32 99.63 27.45 26 94.42 29.71 24 101.63 28.41 21 94.19 30.12 0.9072, F1,43 = 0.01
SPM-P total raw score 31 115.77 29.75 25 112.72 25.60 25 124.40 29.92 21 116.95 30.49 0.8745, F1,43 = 0.03
MSEL, Mullen Scales of Early Learning; ELC, Early Learning Composite; PLS-5, Preschool Language Scales, 5th edition; CGI-I, Clinical Global Impression Scale—
Improvement; VAS, Visual Analog Scale (in units of centimeters); A/OCB, anxiety/obsessive compulsive behavior; L/C, language/communication; A/H/H, aggression/
hyperarousal/hyperactivity; VABS-II ABC, Vineland-II Adaptive Behavior Composite; ABC-C: Aberrant Behavior Checklist—Community; PAS-R, Preschool Anxiety 
Scale—Revised; SRS-2, Social Responsiveness Scale; SPM-P, Sensory Processing Measure—Preschool.
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Safety
There were 313 AEs reported. AEs were similar between treatment 
groups, with the top three most prevalent being upper respiratory 
infection (29 vs. 27%), diarrhea (7 vs. 12%), and hyperactivity (8 
vs. 9%), for sertraline vs. placebo (Table 4). Table 5 summarizes 
the characteristics of AEs by severity, relation to drug, status at 
study exit (resolved or ongoing), and serious AEs. One serious AE, 
hospitalization for dehydration secondary to viral infection, was 
reported in the sertraline group and resolved without sequelae 
or discontinuation of study treatment. No significant differences 
in characteristics of AEs were found between treatment groups: 
severity (Fisher’s exact test, p = 0.146) with mostly mild severity 
(88 vs. 87%, sertraline vs. placebo); relationship to drug (Fisher’s 
exact test, p = 0.641) with 55 vs. 58% not related to drug); and 
whether ongoing at study exit (any ongoing AE: 11 vs. 14%, 
Fisher’s exact test, p = 0.610).
DiSCUSSiOn
Previous studies suggest that some children with ASD may have 
low levels of serotonin during early development, due to either 
low serotonin production in the frontal cortex or deficits in 
the serotonin branch of the tryptophan metabolic pathway, or 
perhaps both (15, 16). Serotonin also appears to be implicated in 
the gastrointestinal dysfunction commonly seen in ASD: a mouse 
model possessing a serotonin transporter mutation (SERT Ala56), 
the most ubiquitous SERT mutation found in children with ASD, 
displays both behavioral and gastrointestinal manifestations of 
ASD, including a hypoplastic enteric nervous system with selective 
impairment in late-born neuronal development and survival (35). 
Treatment with the SSRI fluoxetine rescued this phenotype in mice 
(35). Case reports of children aged 6 to 12 years treated with low-
dose fluoxetine cited rapid and significant improvement in self-
injurious behavior, hyperactivity, irritability, and impulsivity (36). 
A recent national survey reported a caregiver-perceived overall net 
benefit from treatment with sertraline, though significant individual 
response variation was also reported (37). Taken together with 
evidence of greater benefit from targeted treatments during the 
sensitive developmental period, these data suggest the promise of 
SSRIs for treating symptoms of ASD in young children.
However, while several small studies in adults have shown 
promising results (26), Chugani et al. remains the only randomized 
controlled trial of a serotonin-influencing drug in young children 
with idiopathic ASD to date that suggested potential efficacy for 
this purpose (28). Prior to this 2016 trial of low-dose buspirone, five 
studies of treatment with SSRIs in children and adolescents with 
ASD, including a large randomized controlled trial of citalopram 
in individuals 5 to 17 years old, were included in a 2013 review 
concluding that there was insufficient evidence of SSRIs’ efficacy in 
children with ASD (26). However, none of these studies evaluated 
sertraline specifically. Thus, following the positive results of treatment 
with low-dose buspirone in ASD (28) and low-dose sertraline in 
FXS (29, 30), the authors undertook this study to ascertain whether 
sertraline was a beneficial treatment in non-FXS ASD.
The lack of efficacy seen in this study may be due, in part, to the 
extensively heterogenous behavioral manifestations, developmental 
trajectories, and myriad genetic factors at play in idiopathic or 
nonsyndromic ASD. Individual response to study treatment 
varied, and while certain subjects in the sertraline arm saw great 
improvement on the CGI-I, others did not benefit (Figure 2). There 
were no minimum or maximum verbal or other developmental 
requirements to qualify for inclusion in this study, which may 
TABlE 4 | Types of adverse events (AEs).
Sertraline Placebo
Adverse event (AE) n % n %
Upper respiratory infection (URI) 48 28.92 39 26.53
Diarrhea 11 6.63 17 11.56
Hyperactivity 14 8.43 13 8.84
Sleep disturbance 14 8.43 3 2.04
Irritability/aggression 9 5.42 11 7.48
Fever 10 6.02 8 5.44
Vomiting 9 5.42 3 2.04
Gastroenteritis 7 4.22 7 4.76
Ear infection 7 4.22 2 1.36
Rash 1 0.6 6 4.08
Lethargy 3 1.81 5 3.4
Tic 4 2.41 0 0
Constipation 2 1.2 3 2.04
Seasonal allergies 1 0.6 3 2.04
Decreased appetite 3 1.81 1 0.68
Dilated pupils 0 0 2 1.36
Eye redness 0 0 2 1.36
Obsessive behaviors 0 0 2 1.36
Self-injurious behavior 1 0.6 2 1.36
Encopresis 2 1.2 0 0
Increased stimming 2 1.2 1 0.68
Mouthing/chewing objects 2 1.2 0 0
Regression 2 1.2 0 0
Teeth grinding 2 1.2 1 0.68
Cut 0 0 1 0.68
Enuresis 1 0.6 1 0.68
Excessive drooling 0 0 1 0.68
Hand foot mouth disease 0 0 1 0.68
Headaches 0 0 1 0.68
Increase in pica 0 0 1 0.68
Itching 1 0.6 1 0.68
Localized left leg swelling after routine 
immunization
0 0 1 0.68
MRI finding: gray matter heterotopia 0 0 1 0.68
PE tube surgery 0 0 1 0.68
Possible seizure/syncope 0 0 1 0.68
Separation anxiety 1 0.6 1 0.68
Sprained ankle 0 0 1 0.68
Staph infection 0 0 1 0.68
Tuberous sclerosis 0 0 1 0.68
Urinary retention 0 0 1 0.68
Burned feet 1 0.6 0 0
Chicken pox 1 0.6 0 0
Flu 1 0.6 0 0
Gas 1 0.6 0 0
Hoarding 1 0.6 0 0
Inappropriate laughing 1 0.6 0 0
Inattention 1 0.6 0 0
Increased frequency of bowel 
movements
1 0.6 0 0
Tooth pain 1 0.6 0 0
MRI, magnetic resonance imaging.
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have affected detectability of changes on the prespecified outcome 
measures. Additionally, although clinical genetic testing (other 
than FMR1 testing) was not performed as part of this study, some 
caregivers voluntarily consented to add their children’s previous 
results of genetic or MRI testing to the study record. Of those subjects 
with available results, one had Dandy Walker Syndrome, one had 
Wiedemann Steiner Syndrome, one had a 15q13.3 microdeletion, 
one had 21q22.2 deletion, and one had MEF2C and PIK3C2G gene 
variants. All but one of these findings are known in the literature 
to be associated with higher rates of ASD than in the general 
population (38–41). Also, treatment response did not differentially 
follow either baseline BDNF or MMP9 levels, but other biomarkers 
could certainly be correlated. Therefore, genotypic or epigenotypic 
specificity in treatment response may explain the lack of efficacy 
observed in this trial.
This trial includes several limitations important to acknowledge, 
and the results should be considered preliminary. First, the relative 
size of this sample is small; there were significant challenges with 
subject recruitment and retention that may have affected the study’s 
reliability and power to detect efficacy. Many of the 179 caregivers 
contacted about the study declined to participate, expressing 
strong opposition to treating their young child with a psychotropic 
medication so early in life. The second most common reason for 
declining to participate was that the child was already being prescribed 
sertraline or another SSRI. The nature of the enrollment process 
thus selected for those caregivers who were both willing to give their 
TABlE 5 | Characteristics of reported adverse events (AEs).
Variable Category Sertraline Placebo
no. of AEs % no. of AEs % P-value*
Severity Mild 146 87.95 128 87.07 0.1462
Moderate 16 9.64 19 12.93
Severe 4 2.41 0 0
Relationship to drug Not related 91 54.82 85 57.82 0.6408
Possibly related 64 38.55 56 38.1
Probably related 11 6.63 6 4.08
Serious AE No 165 99.4 147 100 1
Yes 1 0.6 0 0
AE status at study exit Ongoing 19 11.45 20 13.61 0.6093
Resolved 147 88.55 127 86.39
*Test-statistic: Fisher’s exact test.
FiGURE 2 | Clinical Global Impression Scale—Improvement at end-of-treatment. CGI-I, Clinical Global Impression Scale—Improvement.
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child an off-label medication and comfortable with the possibility 
that their child would receive placebo. The authors speculate that 
this combination of factors may have biased the sample toward 
two extremes: children who were more severely affected, whose 
caregivers were more willing to consider experimental treatment, 
and children who were higher functioning, whose caregivers were 
more comfortable risking the chance of placebo.
Additionally, the trial drew subjects mainly from the northern 
California area, out of convenience. Thus, the study sample may not 
be representative of the greater population of children with ASD. 
Also, whenever possible, assessments were administered by the same 
rater at baseline and EOT, but in several instances, rater inconsistency 
nevertheless occurred and may have affected the results. The 
relatively high attrition rate observed in the study, coupled with the 
refusal of 11 out of 13 of these early terminated subjects to return for 
EOT assessments, is another limitation. Attrition and recruitment 
issues were likely seen in this study compared to the previous trial 
of sertraline in FXS due to the relative novelty of participating in 
clinical trials of investigational medications for the caregivers of 
children with ASD, whereas caregivers of those with FXS may be 
more readily accepting of treatment with psychotropic interventions 
early in childhood. Future trials of pharmacological interventions 
in young children with ASD could benefit from working with 
community stakeholders to maximize recruitment and retention.
Because the children in this study were followed for 6 months 
during a period in development normally characterized by language 
acquisition and skill development, the authors expected to observe 
significant developmental gains in both the sertraline and placebo 
arms. Thus, the improvement seen on the MSEL, the CGI-I, and 
other outcome measures in the placebo arm is largely explained 
by developmental changes that are typically anticipated at this age. 
Despite caregiver education regarding the placebo effect, there were 
several instances of caregiver ratings of improvement on the CGI-I 
that were not accompanied by significant increases in subjects’ scores 
on developmental assessments. Future studies in this population 
could benefit not only from selection of instruments that offer 
person ability scores that are designed for assessment of change, but 
also from a design that includes additional follow-up assessment 
time points to disentangle change from either measurement error or 
non-treatment-related developmental gains, though care should be 
taken to avoid possible practice effects.
In light of the lack of efficacy in this trial, the authors propose that 
a major factor in the positive response of children with both FXS and 
ASD in the previous controlled trial (29) was the heightened anxiety 
phenotype in the FXS subpopulation. Anxiety disorders, which 
normally affect 15–20% of youths without neurodevelopmental 
disorders, do occur at a high prevalence in individuals with 
ASD, with up to 37% of youth with ASD having been diagnosed 
specifically with social anxiety disorder, and even more (40-60%) 
meeting diagnostic criteria for an anxiety disorder of some kind 
(42–45). Among individuals with FXS, rates of social phobia reach 
between 35–60% and may be underestimated due to diagnostic 
criteria’s reliance on patient expression of “worry,” something not 
all individuals with FXS may do due to their intellectual disability 
(46). Prevalence of social anxiety in males with FXS and ASD 
is higher than that of those with FXS without ASD; specifically, 
initial social avoidance characterizes all males with FXS whereas 
prolonged social avoidance is associated only with the FXS with 
ASD phenotype (46, 47). Furthermore, while rates of anxiety may be 
comparably high between groups compared to typically developing 
controls, recent studies indicate that FXS and ASD may have distinct 
profiles for specific anxiety disorders; indeed, certain aspects of ASD 
symptomatology such as repetition of phrases or topics and gaze 
avoidance may actually reflect anxiety rather than social impairment 
in FXS, suggesting different underlying problems in FXS compared 
to nonsyndromic ASD (48, 49). The authors propose that these 
differences may result from a greater GABA deficit in FXS, leading 
to dampened ability to habituate to sensory stimuli and enhanced 
sympathetic responses to such stimuli, resulting in more intense 
anxiety (50). Regardless of the exact neurobiological mechanism, 
patients in the previous trial of sertraline with syndromic ASD were 
likely to have experienced greater relief from what appears to be a 
unique and heightened manifestation of anxiety compared to their 
peers with FXS or ASD alone, thereby facilitating behavioral or 
attentional improvements that led to greater developmental gains.
Importantly, the side effects of sertraline were not significantly 
different from placebo, and there was one serious AE in the 
sertraline arm that was not related to study treatment. Upon 
study completion, most caregivers opted to obtain a clinical 
prescription for sertraline for their child. Six-month treatment 
at this dose appears to be safe in young children with ASD, 
but follow-up would be essential, particularly if young patients 
continue on this medication for a longer duration.
COnClUSiOn
This preliminary controlled trial demonstrated no benefit of 
sertraline compared to placebo in young children with ASD. Future 
research directions include studies to replicate this trial’s findings, 
additional biomarker testing to examine treatment response 
variability, and long-term follow-up studies to assess the effects of 
low-dose sertraline use in young children later in development.
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